Method for providing modified release of ibuprofen
A method for providing immediate and sustained release of ibuprofen to a subject, including administering, in a single dose, a modified release formulation of ibuprofen including a hydrophilic polymer, ibuprofen in solid dosage form uniformly dispersed in the polymer, and a dissolution additive and an inert formulation additive dispersed in the polymer. The hydrophilic polymer comprises a first hydroxypropyl methylcellulose (HPMC) having a viscosity of about 100 cps and a second HPMC having a viscosity between about 200 cps to about 50,000 cps. The solid dosage form is a monolithic tablet that demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 μg/ml within two hours of administration, and also demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 μg/ml for at least 8 hours after administration.
1. A method for providing immediate and sustained release of ibuprofen to a subject, comprising:
administering to a subject in a single dose a modified release formulation of ibuprofen comprising
a hydrophilic polymer;
300 to 800 mg of ibuprofen in solid dosage form uniformly dispersed in said polymer;
a dissolution additive dispersed in said hydrophilic polymer in an amount in the range of 10% to 35% by weight of the ibuprofen, said dissolution additive comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose sodium, or a combination thereof; and
an inert formulation additive dispersed in said hydrophilic polymer in an amount in the range of 15% to 75% by weight of the ibuprofen,
wherein said hydrophilic polymer comprises a first hydroxypropyl methylcellulose (HPMC) having a viscosity of about 100 cps and a second HPMC having a viscosity between about 200 cps to about 50,000 cps,
wherein said formulation is in a solid dosage form comprising a monolithic tablet and releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate in a substantially linear relationship between percentage of ibuprofen released and elapsed time over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure, and
wherein said tablet demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 μg/ml within two hours of administration, and wherein said tablet also demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 μg/ml for at least 8 hours after administration.
2. The method of claim 1 , wherein ibuprofen is present in the tablet in an amount of about 300 mg, 400 mg, or 600 mg.
3. The method of claim 1 , wherein ibuprofen is present in the tablet in an amount of about 600 mg.
4. The method of claim 1 , wherein each hydroxypropyl methylcellulose is present in the tablet at a concentration of 17% to 42% by weight of the ibuprofen.
5. The method of claim 1 , wherein the viscosity of the second HPMC is about 4,000 cps.
6. The method of claim 1 , wherein the first HPMC is present in the tablet at a concentration in the range of 5% to 20% by weight of the ibuprofen and the second HPMC is present in the tablet at a concentration in the range of about 10% to about 30% by weight of the ibuprofen.
7. The method of claim 1 , wherein said second HPMC has a viscosity selected from the group consisting of 200 cps, 1,000 cps, 2,000 cps, 4,000 cps, 10,000 cps, 15,000 cps, and 50,000 cps.
8. The method of claim 1 , wherein the inert formulation additive comprises a first inert formulation additive having a first average particle size and a second inert formulation additive having a second average particle size, wherein the first and second inert formulation additives are each present in the tablet in an amount in the range of 15% to 35% by weight of the ibuprofen.
9. The method of claim 8 , wherein said first inert formulation additive comprises a first microcrystalline cellulose having the first average particle size and said second inert formulation additive comprises a second crystalline cellulose having the second average particle size, wherein each such microcrystalline cellulose is present in the tablet at a concentration in the range of about 15% to about 35% by weight of the ibuprofen, the combination of which comprises from about 40% to about 60% by weight of the ibuprofen.
10. The method of claim 9 , wherein the first average particle size is about 60 microns and the second average particle size is about 110 microns.
11. The method of claim 1 , wherein the inert formulation additive comprises microcrystalline cellulose.
12. The method of claim 11 , wherein the inert formulation additive further comprises silica, stearic acid, magnesium stearate, lactose, pre-gelatinized starch, dicalcium phosphate, or a combination of any of them.
13. The method of claim 1 , wherein:
the inert formulation additive comprises a first microcrystalline cellulose having a first average particle size and a second microcrystalline cellulose having a second average particle size; and
the dissolution additive comprises glycine as the amino acid having a neutral to alkaline side chain, and croscarmellose sodium.
14. The method of claim 13 , wherein the first and second microcrystalline cellulose comprise silicified microcrystalline cellulose.
15. A method for providing immediate and extended release of ibuprofen to a subject, comprising:
administering to a subject in a single dose of a modified release tablet comprising ibuprofen in an amount in the range of 300 mg to 800 mg per tablet; a hydrophilic polymer; a dissolution additive at a concentration of from 10% to 35% by weight of the ibuprofen comprising an alkali metal salt, an amino acid having a neutral to alkaline side chain, croscarmellose or a salt thereof, or a combination thereof; and an inert formulation additive present in said tablet in an amount of 15% to about 75% by weight of the ibuprofen, wherein said tablet demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 μg/ml within two hours of administration,
wherein said tablet is in a solid dosage form comprising a monolithic tablet and releases at least 20% of the ibuprofen within 2 hours following oral administration or exposure to an agitated aqueous medium of a single dosage unit, then thereafter releases ibuprofen at a relatively constant rate in a substantially linear relationship between percentage of ibuprofen released and elapsed time over a period of at least 8 hours, and wherein at least 70% of the ibuprofen is released over a period of not more than 14 hours following such administration or exposure, and
wherein said tablet also demonstrates a mean ibuprofen plasma concentration in a subject greater than or equal to 6.4 μg/ml for at least 8 hours after administration.